Morgan Stanley’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-4,268,353
| Closed | -$170M | – | 8447 |
|
|
2026
Q1 | $170M | Buy |
4,268,353
+3,159,255
| +285% | +$80.8M | 0.01% | 1054 |
|
|
2025
Q4 | $27.7M | Sell |
1,109,098
-15,347
| -1% | -$389K | ﹤0.01% | 2631 |
|
|
2025
Q3 | $27.3M | Sell |
1,124,445
-669,026
| -37% | -$11.9M | ﹤0.01% | 2580 |
|
|
2025
Q2 | $23.6M | Sell |
1,793,471
-1,143,996
| -39% | -$14.5M | ﹤0.01% | 2638 |
|
|
2025
Q1 | $42.2M | Buy |
2,937,467
+1,012,958
| +53% | +$16.6M | ﹤0.01% | 1959 |
|
|
2024
Q4 | $32.2M | Buy |
1,924,509
+544,858
| +39% | +$9.03M | ﹤0.01% | 2263 |
|
|
2024
Q3 | $22.1M | Sell |
1,379,651
-670,741
| -33% | -$8.22M | ﹤0.01% | 2702 |
|
|
2024
Q2 | $18.5M | Sell |
2,050,392
-86,973
| -4% | -$825K | ﹤0.01% | 2749 |
|
|
2024
Q1 | $24.2M | Buy |
2,137,365
+923,315
| +76% | +$8.74M | ﹤0.01% | 2497 |
|
|
2023
Q4 | $9.66M | Buy |
1,214,050
+256,099
| +27% | +$1.72M | ﹤0.01% | 3375 |
|
|
2023
Q3 | $6.2M | Buy |
957,951
+133,322
| +16% | +$912K | ﹤0.01% | 3561 |
|
|
2023
Q2 | $5.1M | Buy |
824,629
+80,722
| +11% | +$383K | ﹤0.01% | 3766 |
|
|
2023
Q1 | $2.86M | Buy |
743,907
+428,772
| +136% | +$1.57M | ﹤0.01% | 4218 |
|
|
2022
Q4 | $977K | Buy |
315,135
+298,641
| +1,811% | +$1.11M | ﹤0.01% | 4886 |
|
|
2022
Q3 | $67K | Sell |
16,494
-23,770
| -59% | -$109K | ﹤0.01% | 6264 |
|
|
2022
Q2 | $196K | Buy |
40,264
+18,652
| +86% | +$119K | ﹤0.01% | 5911 |
|
|
2022
Q1 | $194K | Buy |
21,612
+7,527
| +53% | +$68.6K | ﹤0.01% | 5938 |
|
|
2021
Q4 | $158K | Buy |
14,085
+6,455
| +85% | +$86.9K | ﹤0.01% | 6182 |
|
|
2021
Q3 | $128K | Buy |
+7,630
| New | +$158K | ﹤0.01% | 6223 |
|
Morgan Stanley's CNTA Position: Q2 2026 in Review
Morgan Stanley sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 4,268,353 shares — an estimated $170M sold.
Morgan Stanley first reported a position in CNTA in Q3 2021 and held it in 19 quarters. The position peaked at $170M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Morgan Stanley reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Morgan Stanley sold 4,268,353 Centessa Pharmaceuticals shares in Q2 2026, an estimated $170M.
- Morgan Stanley first reported a position in Centessa Pharmaceuticals in Q3 2021 and held it in 19 quarters.
- Morgan Stanley's Centessa Pharmaceuticals position peaked at $170M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.